RecruitingNCT06514521

Post Marketing Study on Pluvicto in Korea

A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting

Sponsor

Novartis Pharmaceuticals

Enrollment

278 participants

Start Date

Apr 18, 2025

Study Type

OBSERVATIONAL

Conditions

Metastatic Castration-resistant Prostate Cancer

Summary

Post marketing study on Pluvicto in Korea

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This post-marketing observational study is tracking real-world outcomes for male patients in South Korea who are receiving Pluvicto (lutetium-177 PSMA) — a targeted radioligand therapy — for prostate cancer, as part of routine clinical care after the drug's approval. **You may be eligible if...** - You are a male patient aged 18 or older in South Korea - You are currently being treated with Pluvicto, or your doctor has already finalized a treatment plan to start Pluvicto - You have provided written informed consent to participate **You may NOT be eligible if...** - Your medical records are not accessible - You are unwilling to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERLutetium vipivotide tetraxetan

This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement.